A Clinical Trial of Prophylactic Prostatectomy for BRCA2 Mutation Carriers: Is Now the Time?

Roderick Clark; Kristen McAlpine; Neil Fleshner

doi:10.1016/j.euf.2021.04.018

A Clinical Trial of Prophylactic Prostatectomy for BRCA2 Mutation Carriers: Is Now the Time?

Eur Urol Focus. 2021 May;7(3):506-507. doi: 10.1016/j.euf.2021.04.018. Epub 2021 May 11.

Authors

Roderick Clark¹, Kristen McAlpine², Neil Fleshner²

Affiliations

¹ Division of Urology, University of Toronto, Toronto, Canada. Electronic address: roderick.clark@uhn.ca.
² Division of Urology, University of Toronto, Toronto, Canada.

PMID: 33994169
DOI: 10.1016/j.euf.2021.04.018

Abstract

The greater availability and use of genetic testing have improved our ability to determine that men with BRCA2 mutations are at significantly higher risk of developing and dying of prostate cancer. We should continue research efforts in secondary prevention for this population, but must also explore primary preventative strategies such as prophylactic prostatectomy. Efforts are under way at our institution for a clinical trial in this area.

Publication types

Editorial

MeSH terms

BRCA2 Protein / genetics
Clinical Trials as Topic
Genes, BRCA2*
Genetic Testing
Humans
Male
Mutation
Prostatectomy
Prostatic Neoplasms* / genetics
Prostatic Neoplasms* / prevention & control
Prostatic Neoplasms* / surgery

Substances

BRCA2 Protein
BRCA2 protein, human